My work is focused on comparing the clinical effects of newer antipsychotics in people with schizophrenia, including those who are refractory to therapy using trials with a similar strategy to the one that defined clozapine as a differentially effective antipsychotic. Our group performs large clinical trials, outcome studies and human post-mortem studies. Our group provides the clinical characterization of the subjects in the Maryland Brain Collection. We have a primary interest in the binding patterns of antipsychotic medication in the human brain and antipsychotic-induced changes in the ultrastructure of the human synapse. We also actively work in the area of research ethics, particularly in the area of evaluation of ability to consent to research trials.
